Acceleron Pharma Inc. (XLRN) Hit 1-Year High at $48.80

June 29, 2018 - By Bridget Boland

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

During 2018 Q1 the big money sentiment increased to 1.27. That’s change of 0.18, from 2017Q4’s 1.09. 13 investors sold all, 39 reduced holdings as Acceleron Pharma Inc. ratio is positive. 42 grew positions while 24 funds acquired positions. Funds hold 38.30 million shares thus 0.44% more from 2017Q4’s 38.14 million shares.
First Trust Advisors Lp invested in 32,354 shs or 0% of the stock. Hillhouse Capital Mgmt Ltd holds 0.48% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN) for 700,000 shs. Citadel Advsr Limited Liability Company reported 0% stake. Goldman Sachs Grp Incorporated, a New York-based fund reported 555,019 shs. Fmr Ltd Llc has 5.17M shs for 0.02% of their capital. Schwab Charles Invest Mngmt holds 0.01% or 192,271 shs in its capital. Aqr Cap Mngmt Lc, Connecticut-based fund reported 9,537 shs. Manufacturers Life Ins The, a Ontario – Canada-based fund reported 28,217 shs. Morgan Stanley reported 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). 1.40M were reported by Farallon Management Ltd. Platinum Inv Management Ltd stated it has 0.06% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Bnp Paribas Arbitrage holds 7,769 shs or 0% of its capital. 4,537 are owned by C Wide Group A S. Omega Advsrs stated it has 45,000 shs or 0.07% of all its holdings. Franklin Res accumulated 435,577 shs.

Acceleron Pharma Inc. registered $4.08 million net activity with 0 buys and 12 insider sales since January 2, 2018. On Tuesday, January 2 a trade for 4,300 shs valued at $182,363 was made by Kumar Ravindra. On Wednesday, January 3 $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Sherman Matthew L. MCLAUGHLIN KEVIN F sold $814,848 worth of stock. Another trade for 37,500 shs valued at $1.55M was sold by POPS RICHARD F. On Tuesday, April 3 $134,395 worth of stock was sold by Rovaldi Christopher.

The company Acceleron Pharma Inc. (NASDAQ:XLRN) hit yearly high with $52.70 PT or 8.00 % above today’s $48.80 price per share. On Jun, 29 it was published by Barchart.com. The company has $2.23B market cap. At $52.70 stock PT, the company valuation changes by $178.72 million more.

The stock increased 43.61% or $14.82 during the last trading session, hitting $48.8.Acceleron Pharma Inc. has 3.15 million shares volume, 862.44% up from normal. XLRN is uptrending and has moved 37.77% since June 29, 2017. XLRN outperformed by 25.20% the S&P500.

Acceleron Pharma Inc. (NASDAQ:XLRN)’s earnings report is anticipated on August, 2., as reported by Faxor. Analysts forecast 16.88 % diference or $-0.64 from the $-0.77 EPS from 2017. Wall Street now predicts 10.34 % negative EPS growth despite Acceleron Pharma Inc. previous quarter’s EPS of $-0.58.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

In total 7 analysts cover Acceleron Pharma (NASDAQ:XLRN). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. (NASDAQ:XLRN) has 71% bullish analysts. With $63 highest and $40 lowest price target, Acceleron Pharma has $52 average price target or 6.56% above the current ($48.8) price. 9 are the (NASDAQ:XLRN)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. The company rating was initiated by H.C. Wainwright on Wednesday, March 28. On Friday, June 29 the firm has “Neutral” rating by Goldman Sachs given. On Wednesday, February 28 Barclays Capital maintained Acceleron Pharma Inc. (NASDAQ:XLRN) with “Overweight” rating. On Monday, January 8 the rating was initiated by H.C. Wainwright with “Buy”. On Friday, June 29 the firm has “Outperform” rating given by Credit Suisse. On Thursday, March 1 the stock has “Buy” rating by Citigroup. On Wednesday, February 28 the stock has “Buy” rating by H.C. Wainwright. On Tuesday, May 22 the rating was initiated by Oppenheimer with “Hold”. The stock rating was upgraded by JP Morgan to “Overweight” on Monday, February 26.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news brought out recently go to: Businesswire.com, Streetinsider.com, Globenewswire.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society” brought out on June 26, 2018, “Acceleron Pharma (XLRN) Highlights Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia” on June 15, 2018, “Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination …” with a publish date: June 22, 2018, “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” and the last “Acceleron: Luspatercept New Data Is A Buy Signal” with publication date: June 07, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The company has $2.23 billion market cap. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Currently it has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.